Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1803 1
1844 1
1845 3
1846 1
1850 1
1852 1
1853 2
1854 2
1855 1
1856 2
1861 1
1862 1
1867 1
1878 1
1888 1
1889 1
1901 1
1905 1
1910 1
1911 1
1912 4
1913 3
1914 1
1915 3
1916 3
1917 8
1918 3
1919 1
1920 2
1921 6
1922 3
1923 3
1925 1
1926 4
1927 1
1930 1
1932 1
1936 1
1938 2
1939 2
1940 1
1942 1
1944 2
1945 1
1946 6
1947 6
1948 13
1949 19
1950 20
1951 20
1952 15
1953 31
1954 27
1955 22
1956 34
1957 17
1958 21
1959 19
1960 18
1961 14
1962 18
1963 19
1964 25
1965 35
1966 29
1967 43
1968 40
1969 44
1970 50
1971 50
1972 65
1973 60
1974 54
1975 79
1976 68
1977 65
1978 82
1979 60
1980 57
1981 64
1982 55
1983 75
1984 89
1985 91
1986 90
1987 79
1988 107
1989 105
1990 135
1991 121
1992 128
1993 97
1994 109
1995 118
1996 135
1997 119
1998 126
1999 135
2000 153
2001 153
2002 151
2003 179
2004 186
2005 191
2006 198
2007 212
2008 195
2009 203
2010 232
2011 287
2012 284
2013 340
2014 315
2015 321
2016 380
2017 388
2018 359
2019 332
2020 350
2021 398
2022 405
2023 273

Text availability

Article attribute

Article type

Publication date

Search Results

9,133 results

Results by year

Filters applied: . Clear all
Page 1
Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo.
Rosmarin D, Passeron T, Pandya AG, Grimes P, Harris JE, Desai SR, Lebwohl M, Ruer-Mulard M, Seneschal J, Wolkerstorfer A, Kornacki D, Sun K, Butler K, Ezzedine K; TRuE-V Study Group. Rosmarin D, et al. Among authors: harris je. N Engl J Med. 2022 Oct 20;387(16):1445-1455. doi: 10.1056/NEJMoa2118828. N Engl J Med. 2022. PMID: 36260792
Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial.
Ezzedine K, Peeva E, Yamaguchi Y, Cox LA, Banerjee A, Han G, Hamzavi I, Ganesan AK, Picardo M, Thaçi D, Harris JE, Bae JM, Tsukamoto K, Sinclair R, Pandya AG, Sloan A, Yu D, Gandhi K, Vincent MS, King B. Ezzedine K, et al. Among authors: harris je. J Am Acad Dermatol. 2023 Feb;88(2):395-403. doi: 10.1016/j.jaad.2022.11.005. Epub 2022 Nov 9. J Am Acad Dermatol. 2023. PMID: 36370907 Free article. Clinical Trial.
Molecular architecture determines brain delivery of a transferrin receptor-targeted lysosomal enzyme.
Arguello A, Mahon CS, Calvert MEK, Chan D, Dugas JC, Pizzo ME, Thomsen ER, Chau R, Damo LA, Duque J, Fang M, Giese T, Kim DJ, Liang N, Nguyen HN, Solanoy H, Tsogtbaatar B, Ullman JC, Wang J, Dennis MS, Diaz D, Gunasekaran K, Henne KR, Lewcock JW, Sanchez PE, Troyer MD, Harris JM, Scearce-Levie K, Shan L, Watts RJ, Thorne RG, Henry AG, Kariolis MS. Arguello A, et al. Among authors: harris jm. J Exp Med. 2022 Mar 7;219(3):e20211057. doi: 10.1084/jem.20211057. Epub 2022 Feb 28. J Exp Med. 2022. PMID: 35226042 Free PMC article.
Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia.
Xia D, Lianoglou S, Sandmann T, Calvert M, Suh JH, Thomsen E, Dugas J, Pizzo ME, DeVos SL, Earr TK, Lin CC, Davis S, Ha C, Leung AW, Nguyen H, Chau R, Yulyaningsih E, Lopez I, Solanoy H, Masoud ST, Liang CC, Lin K, Astarita G, Khoury N, Zuchero JY, Thorne RG, Shen K, Miller S, Palop JJ, Garceau D, Sasner M, Whitesell JD, Harris JA, Hummel S, Gnörich J, Wind K, Kunze L, Zatcepin A, Brendel M, Willem M, Haass C, Barnett D, Zimmer TS, Orr AG, Scearce-Levie K, Lewcock JW, Di Paolo G, Sanchez PE. Xia D, et al. Among authors: harris ja. Mol Neurodegener. 2022 Jun 11;17(1):41. doi: 10.1186/s13024-022-00547-7. Mol Neurodegener. 2022. PMID: 35690868 Free PMC article.
AUTHOR REPLY.
Turner EN, Talwar R, Familusi OO, Michel K, Harris JEL, Ziemba J. Turner EN, et al. Among authors: harris jel. Urology. 2022 May;163:201. doi: 10.1016/j.urology.2022.01.074. Urology. 2022. PMID: 35636851 No abstract available.
Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR.
Schwarz M, Torre D, Lozano-Ojalvo D, Tan AT, Tabaglio T, Mzoughi S, Sanchez-Tarjuelo R, Le Bert N, Lim JME, Hatem S, Tuballes K, Camara C, Lopez-Granados E, Paz-Artal E, Correa-Rocha R, Ortiz A, Lopez-Hoyos M, Portoles J, Cervera I, Gonzalez-Perez M, Bodega-Mayor I, Conde P, Oteo-Iglesias J, Borobia AM, Carcas AJ, Frías J, Belda-Iniesta C, Ho JSY, Nunez K, Hekmaty S, Mohammed K, Marsiglia WM, Carreño JM, Dar AC, Berin C, Nicoletti G, Della Noce I, Colombo L, Lapucci C, Santoro G, Ferrari M, Nie K, Patel M, Barcessat V, Gnjatic S, Harris J, Sebra R, Merad M, Krammer F, Kim-Schulze S, Marazzi I, Bertoletti A, Ochando J, Guccione E. Schwarz M, et al. Among authors: harris j. Nat Biotechnol. 2022 Nov;40(11):1680-1689. doi: 10.1038/s41587-022-01347-6. Epub 2022 Jun 13. Nat Biotechnol. 2022. PMID: 35697804
Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled, double-blind phase I/Ib studies in healthy subjects and patients.
Vissers MFJM, Heuberger JAAC, Groeneveld GJ, Oude Nijhuis J, De Deyn PP, Hadi S, Harris J, Tsai RM, Cruz-Herranz A, Huang F, Tong V, Erickson R, Zhu Y, Scearce-Levie K, Hsiao-Nakamoto J, Tang X, Chang M, Fox BM, Estrada AA, Pomponio RJ, Alonso-Alonso M, Zilberstein M, Atassi N, Troyer MD, Ho C. Vissers MFJM, et al. Among authors: harris j. Clin Transl Sci. 2022 Aug;15(8):2010-2023. doi: 10.1111/cts.13317. Epub 2022 Jun 1. Clin Transl Sci. 2022. PMID: 35649245 Free PMC article. Clinical Trial.
9,133 results